Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer

Tomozawa, Shigeru; Tsuno, Nelson H.; Sunami, Eiji; Hatano, Kenji; Kitayama, Joji; Osada, Takuya; Saito, Shinsuke; Tsuruo, Takashi; Shibata, Yoichi; Nagawa, Hirokazu

doi:10.1054/bjoc.2000.1270

Cited by 202 publications

(156 citation statements)

References 27 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…There is insignificant relationship between COX-2 immunostaining and site, size and gross appearance of the tumor (where most of cases in all sites are positive for COX-2). Similar results were reported by (Tomozawa et al, 2000),after working on 63 patients with advanced colorectal cancer; in which COX-2 positivity appear in all cases examined; found that there was no significant correlation between COX-2 expression and tumor location, age, sex, tumor size, histological type, depth of invasion, lymphatic or venous invasion, lymph-nodemetastasis. According to (Soumaoro et al, 2004) 51 % of histological grading belongs to Grade II in the colorectal adenocarcinoma cases this result is similar to our work.…”

Section: Discussionsupporting

confidence: 86%

“…The role of angiogenesis is very important in colorectal cancer and cancercyclooxygenase-2 is a significant angiogenic factor in colorectal cancer tissue (Zhou et al, 2012). Cox-2 is expressed highly in 80-90% of colorectal adenocarcinoma mostly within the neoplastic epithelial cells (Zhang et al, 2002), (Tomozawa et al, 2000). Selective inhibition of Cox-2 reduces colorectal cancer in different models of carcinogenesis (Tuynman et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of Cyclooxygenase-2 (COX-2) in Colorectal Adenocarcinoma: an Immunohistochemical and Histopathological Study

Mahmoud

Umair²,

Azzeghaiby³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate cyclooxygenase-2 (COX-2) immunoreactivity in colorectal adenocarcinomas and to find correlations with different pathological features. Materials and Methods: This study included 35 cases of colorectal carcinoma foir which surgical colectomy specimens were collected. Immunohistochemical staining of COX-2 (cyclooxygenase-2) is done by using the Streptavidin-biotin technique. Results: This work reveals that COX-2 is positive in most cases of colorectal carcinoma and negative in normal colon tissue with statistically non significant relations between COX-2 immunostaining and different pathological features. Conclusions: Our data suggest over expression of COX-2 protein in colorectal carcinoma in contrast to normal mucosa, with a possible role in cell proliferation in carcinogenesis.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Expression of Cyclooxygenase-2 (COX-2) in Colorectal Adenocarcinoma: an Immunohistochemical and Histopathological Study

Mahmoud

Umair²,

Azzeghaiby³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…It has been reported that COX-2 overexpression is associated with inhibition of apoptosis and host immune responses, and increased metastatic potential and neoangiogenesis (Tsujii and Dubois, 1995;Tsujii et al, 1998;Stolina et al, 2000). In this context, it is not surprising that COX-2 has been associated with parameters of tumour aggressiveness and unfavourable clinical outcome in several solid tumours (Ferrandina et al, 2002a;Tomozawa et al, 2000;Ristimaki et al, 2002). As far as cervical cancer is concerned, recent reports showed that high COX-2 expression is associated with diminished survival in cervical cancer patients administered radiotherapy (Gaffney et al, 2001).…”

mentioning

confidence: 98%

Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications

et al. 2002

View full text Add to dashboard Cite

This study aims at investigating the relationship between cyclooxygenase-2 expression in tumour vs stroma inflammatory compartment and its possible clinical role. The study included 99 stage IB-IV cervical cancer patients: immunostaining of tumour tissue sections was performed with rabbit antiserum against cyclooxygenase-2. CD3, CD4, CD8, CD25, Mast Cell Tryptase monoclonal antibodies were used to characterise stroma inflammatory cells in nine cervical tumours. An inverse relation was found between cyclooxygenase-2 levels (cyclooxygenase-2 IDV) of tumour vs stroma compartment (r=70.44, P50.0001). The percentage of cases showing high tumour/stromal cyclooxygenase-2 IDV ratio was significantly higher in patients who did not respond to treatment (93.3%) with respect to patients with partial (60.5%), and complete (43.7%) response (P= 0.009). Cases with a high tumour/stroma cyclooxygenase-2 IDV ratio had a shorter overall survival rate than cases with a low tumour/stroma cyclooxygenase-2 IDV (P50.0001). In the multivariate analysis advanced stage and the status of tumour/stroma cyclooxygenase-2 IDV ratio retained an independent negative prognostic role. The proportion of CD3 + , CD4 + , and CD25 + cells was significantly lower in tumours with high tumour/stroma cyclooxygenase-2 IDV ratio, while a higher percentage of mast cells was detected in tumours showing high tumour/stroma cyclooxygenase-2 IDV ratio. Our study showed the usefulness of assessing cyclooxygenase-2 status both in tumour and stroma compartment in order to identify cervical cancer patients endowed with a very poor chance of response to neoadjuvant therapy and unfavourable prognosis.

show abstract

“…10,28 Investigating such a correlation is also important to understand prostate cancer progression because at least in experimental models of prostate cancer, COX-2 overexpression leads to increase in aggression of tumor cells, higher secretion of angiogenic factors and metastasis. [43][44][45][46] In this study, we investigated COX-2 expression in archival radical prostatectomy specimens from random samples of 60 prostate cancer patients on whom a minimum 62-month follow-up was available. Our results show that COX-2 expression in prostate cancer cells is an independent prognostic indicator for predicting biochemical recurrence.…”

mentioning

confidence: 99%

Cyclooxygenase‐2 (cox‐2) expression is an independent predictor of prostate cancer recurrence

Cohen

Gómez

Omori

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Lack of reliable prognostic markers hinders accurate prediction of disease progression in prostate cancer. The inducible proinflammatory enzyme cyclooxygenase-2 (COX-2) is implicated in prostate carcinogenesis, but its role in cancer progression is less clear. We examined whether COX-2 expression evaluated by immunohistochemistry (IHC) in radical prostatectomy (RP) specimens can predict biochemical recurrence. Archival prostate cancer specimens (n 5 60) were obtained from patients who underwent RP, but had not received neoadjuvant hormonal therapy. Twentythree patients had biochemical or clinical recurrence (mean time of recurrence: 38.2 months), and 37 patients were recurrence free (mean follow-up: 95 months). COX-2 expression was determined by IHC, using an anti-COX-2 antibody. Three individuals scored the staining independently, as high-or low-expression. COX-2 was expressed in prostate cancer cells, in adjacent normal glands and in specimens from patients who later progressed. At 62-months follow-up, COX-2 staining predicted progression with 82.4% sensitivity and 81.3% specificity. Sensitivity (86.4%) and specificity (86.7%) improved at 100-months follow-up. In univariate analysis, Gleason score, preoperative PSA, extraprostatic extension, margin, seminal vesicle invasion, and high COX-2 expression were significant predictors of biochemical recurrence (p < 0.05). In multivariate analysis, preoperative PSA (hazard ratio/unit PSA change 1.080; p 5 0.0036) and COX-2 expression (hazard ratio 16.442; p < 0.0001) were independent prognostic indicators. Patients with PSA > 7 ng/ml and high COX-2 expression had the highest probability of recurrence (Kaplan-Meier analysis). COX-2 expression is an independent predictor of prostate cancer progression following RP and underscores the significance of inflammatory factors in this process. ' 2006 Wiley-Liss, Inc.Key words: inflammation; immunohistochemistry; PSA; cancer progression; prognostic indicators; multivariate analysis; tumor markers Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) are prostaglandin endoperoxide synthases, which are rate limiting enzymes in the conversion of the fatty acid arachidonic acid into physiologically active eicosanoids such as prostaglandin, thromboxane and prostacyclin. 1 COX-2 is the inducible form of COX that is frequently elevated in cancer tissues. [2][3][4] Although the mechanism of COX-2 action in carcinogenesis or progression is not well established, COX-2 inhibitors have been shown to be chemopreventive in cancer, specifically in colorectal cancer. [5][6][7] The expression and role of COX-2 in prostate cancer has been a topic of several reports over the decade. 8,9 There exists some controversy over the expression, detection and the putative role of COX-2 in prostate carcinogenesis and progression. While early studies reported high-level expression of COX-2 in prostate, findings from subsequent studies have been mixed. [10][11][12] Typically, later studies reported low or no expression in normal, benign prostatic hyperplasi...

show abstract

Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer

Cited by 202 publications

References 27 publications

Expression of Cyclooxygenase-2 (COX-2) in Colorectal Adenocarcinoma: an Immunohistochemical and Histopathological Study

Expression of Cyclooxygenase-2 (COX-2) in Colorectal Adenocarcinoma: an Immunohistochemical and Histopathological Study

Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications

Cyclooxygenase‐2 (cox‐2) expression is an independent predictor of prostate cancer recurrence

Contact Info

Product

Resources

About